Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-22T08:38:19.910Z Has data issue: false hasContentIssue false
  • English
  • Français

“Continuous” Thioproperazine

A Controlled Trial in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

E. C. MacLeod  and
J. Moffat
E. C. MacLeod
Affiliation:
Department of Psychological Medicine, Southern General Hospital, Glasgow; Glasgow Royal Mental Hospital
J. Moffat
Affiliation:
Glasgow Royal Mental Hospital
Get access Rights & Permissions [Opens in a new window]

Extract

Thioproperazine (‘Majeptil’) is a recently introduced phenothiazine derivative which readily produces extra-pyramidal disturbances. Its pharmacology was originally described by Courvoisier et al. (1958) and its clinical properties by a number of workers including, in this country, Denham and Carrick (1961). Several investigators have reported impressive results with this drug in a variety of mentally ill patients, including chronic schizophrenics who had failed to respond to other forms of therapy.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 109 , Issue 461 , July 1963 , pp. 531 - 535
Copyright
Copyright © Royal College of Psychiatrists, 1963

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baker, A. A., and Thorpe, J. G. (1956). “Some simple measures of schizophrenic deterioration”, J. Ment. Sci., 102, 838–846.CrossRefGoogle Scholar
Courvoisier, S., Ducrot, R., Fournel, J., and Julou, L. (1958). “Propriétés pharmacologiques générales de la 3-diméthyl-sulphonamide-10[3-(4-méthylpiperazinyl)propyl] phénothiazine (7843 R.P.)”. Report to Congr. Psychiat. Neurol., Strasbourg.Google Scholar
Crammond, W. A. (1962). “Thioproperazine”, Lancet, i, 592–593.CrossRefGoogle Scholar
Delay, J., Deniker, P., Ropert, R., Beek, N., Barande, R., and Eurieult, M. (1959a). “Syndromes neurologiques expérimentaux et thérapeutique psychiatrique. I. Effets neurologiques d'un nouveau neuroleptique majeur, le 7843 R.P.”, Presse Medicale, 67, 123–126.Google Scholar
Delay, J., Deniker, P., Ropert, R., Beek, N., Barande, R., and Eurieult, M. (1959b). “Effets psychiques et thérapeutiques d'un nouveau neuroleptique majeur, le 7843 R.P. Etude polygraphique”, Ibid., 67, 201–207.Google Scholar
Denber, H. C. B., Rajotte, P., and Kauffman, D. (1959). “Clinical experiences with a new phenothiazine”, Amer. J. Psychiat., 115, 1116–1117.CrossRefGoogle Scholar
Denham, J., and Carrick, D. J. E. L. (1961). “Therapeutic value of thioproperazine and the importance of the associated neurological disturbances”, J. Ment. Sci., 107, 326–345.CrossRefGoogle Scholar
Foulds, G. A. (1958). “Clinical research in psychiatry”, Ibid., 104, 259–265.Google Scholar
Fox, B. (1961). “The investigation of the effects of psychiatric treatment”, Ibid., 107, 493–502.Google Scholar
Lancet. (1961). “Thioproperazine”, ii, 698.Google Scholar
Maurel, H., Perrin, J., Spielmann, J. P., and Sifferman, A. (1960a). “Etude préliminaire des résultats obtenus par la thioproperazine en thérapeutique psychiatrique”, Ann. Méd-Psychol., 118, 577–581.Google Scholar
Maurel, H., Perrin, J., Spielmann, J. P., and Sifferman, A. (1960b). “Pratique psychiatrique hospitalier de la thiopropérazine. Comparaison avec la prochlorpérazine”, Ibid., 118, (1), 987–984.Google Scholar
Ollendorff, R. H. V. (1962). “Reactions to thioproperazine (‘Majeptil’)”, Brit. Med. J., 1, 1074.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.